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PCircumferential Strain Analysis Identifies Strata
of Cardiomyopathy in Duchenne Muscular Dystrophy
A Cardiac Magnetic Resonance Tagging Study
Kan N. Hor, MD,* Janaka Wansapura, PHD,† Larry W. Markham, MD,‡ Wojciech Mazur, MD,§
Linda H. Cripe, MD,* Robert Fleck, MD,† D. Woodrow Benson, MD, PHD,*
William M. Gottliebson, MD*
Cincinnati, Ohio; and Nashville, Tennessee
Objectives This study sought to evaluate the natural history of occult cardiac dysfunction in Duchenne muscular dystrophy
(DMD).
Background Duchenne muscular dystrophy is characterized by progressive cardiac dysfunction and myocardial fibrosis late in the
disease process. We hypothesized that left ventricular myocardial peak circumferential strain (cc) would decrease in
DMD before global systolic functional abnormalities regardless of age or ventricular ejection fraction (EF).
Methods We evaluated cardiac magnetic resonance image (MRI) data from 70 DMD patients and 16 aged-matched con-
trol subjects. Standard imaging data included steady-state free precession short-axis cine stack images, cine
myocardial tagged images, and myocardial delayed enhancement (MDE) (an indicator of myocardial fibrosis)
sequences. Analysis was performed with QMASS (Medis Medical Imaging Systems, Leiden, the Netherlands) and
HARP (Diagnosoft, Palo Alto, California) software. The DMD patient data were subdivided by age (10 or 10
years), EF (55% or 55%), and the presence or absence of MDE.
Results The DMD patients with normal EF had reduced cc at an early age (10 years) compared with control subjects
(p  0.01). The DMD patients age 10 years with normal EF had further decline in cc compared with younger
DMD patients (p  0.01). There was further decline in cc with age in patients with reduced EF (p  0.01) with-
out MDE. The oldest patients, with both reduced EF and positive MDE, exhibited the lowest cc. None of the pa-
tients had ventricular hypertrophy.
Conclusions Myocardial strain abnormalities are prevalent in young DMD patients despite normal EF, and these strain values
continue to decline with advancing age. Strain analysis in combination with standard MRI and MDE imaging pro-
vides a means to stratify DMD cardiomyopathy. (J Am Coll Cardiol 2009;53:1204–10) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.032m
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tuchenne muscular dystrophy (DMD), an X-linked reces-
ive disorder affecting approximately 1 in 3,500 male sub-
ects (1), results from a mutation in the gene that encodes
ystrophin, a sarcolemmal protein abundant in skeletal and
ardiac muscle cells (1). DMD is characterized by progres-
ive skeletal muscle weakness, with loss of ambulation
etween the ages of 7 and 13 years. Death secondary to
ardiac or respiratory failure typically occurs in the second or
hird decade. Cardiac disease manifests as a dilated cardio-
rom the Departments of *Cardiology and †Radiology, Cincinnati Children’s
ospital Medical Center, Cincinnati, Ohio; ‡Department of Pediatric Cardiology,
anderbilt University, Nashville, Tennessee; and the §Christ Hospital, Cincinnati,
hio. This work was supported in part by the Children’s Heart Association of
incinnati (to Dr. Gottliebson) and the National Institutes of Health grant
L069712 (to Dr. Benson), Bethesda, Maryland.m
Manuscript received June 17, 2008; revised manuscript received October 31, 2008,
ccepted December 18, 2008.yopathy (2,3). End-stage cardiac pathology consists of
lternating areas of myocyte hypertrophy, atrophy, and
brosis (3,4).
Use of corticosteroids and supportive respiratory care
5–7) have improved outcomes in DMD patients such that
ardiomyopathy is now the leading cause of death (8). The
rogression of cardiomyopathy does not correlate to the
everity of skeletal muscle weakness, and early manifesta-
ions of heart failure in DMD patients often go unrecog-
ized due to lack of classic signs and symptoms (9). Previous
nvestigators have demonstrated that cardiac disease is
nderway long before symptoms appear (10–12).
Traditionally, assessment of global cardiac function has
een evaluated via transthoracic echocardiography (TTE)
2,13,14). However, this modality has proved challenging in
he DMD population. TTE rarely detects functional abnor-
alities during the first decade (15), and acoustic windows
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April 7, 2009:1204–10 Myocardial Strain in Duchenne Muscular Dystrophyn DMD patients tend to be limited due to altered body
abitus, including scoliosis and significant chest wall adi-
osity. To overcome these limitations, our center and others
ave turned to cardiac magnetic resonance imaging (MRI)
or primary screening of global cardiac function in DMD
atients (16–18). Recent reports have shown that occult
ardiac dysfunction (19) and myocardial fibrosis (16) can be
iagnosed by MRI in DMD patients. However, the natural
istory of the cardiac dysfunction, manifest as reduction in
eak left ventricular myocardial circumferential strain (cc), has
ot been reported. We hypothesized that abnormalities of cc
ould exist early in the course of DMD cardiomyopathy
espite normal ejection fraction (EF) and would be progressive
uring the course of the disease, as cardiac dysfunction be-
omes more generalized.
ethods
tudy population. Data were analyzed from records of
MD patients followed at Cincinnati Children’s Hospital
edical Center. The diagnosis of DMD was confirmed by
skeletal muscle biopsy showing absent dystrophin and/or
eoxyribonucleic acid analysis demonstrating a characteris-
ic dystrophin mutation in all patients.
RI inclusion and exclusion criteria. The DMD pa-
ients who underwent clinical MRI studies between Sep-
ember 2005 and September 2007 were included in this
nalysis. Only quality tagged cine MRIs were included for
nalysis (confirmed by 3 independent expert readers: R.J.F.,
.M.G., and K.N.H.). An age-matched control group
Figure 1 Group Stratification
Stratification of Duchenne muscular dystrophy (DMD) patients is based on age, ejectionderwent an identical protocol.
ll subjects (control subjects and
MD patients) were5 years of
ge, thereby eliminating the need
or sedation. The MRI studies
ere performed on 97 DMD
atients between September
005 and September 2007. Data
rom 27 of 97 patients was ex-
luded due to absence of tagged
mages (n  18) or poor tag
uality secondary to breathing
rtifact or patient movement (n
9). The Institutional Review
oard at the Cincinnati Chil-
ren’s Hospital Medical Center
pproved the study.
ubject stratification. The subject data were stratified into
groups: Group A (control subjects) and Groups B to E
DMD patients), grouped according to age, EF, and the
resence of myocardial fibrosis on the basis of positive
yocardial delayed enhancement (MDE) imaging (Fig. 1).
ecause prior studies have rarely identified cardiac dysfunc-
ion before age 10 years (15), we stratified DMD patients
10 or 10 years. As such, Group B comprised DMD
atients age10 years with normal EF and negative MDE.
ecause MDE has usually been associated with advanced
ardiac disease, patients 10 years were further stratified by
DE status (i.e., with or without MDE). Lastly, we
tion (EF), and presence or absence of myocardial delayed enhancement (MDE).
Abbreviations
and Acronyms
DMD  Duchenne muscular
dystrophy
ECG  electrocardiogram
cc  circumferential strain
EF  ejection fraction
MDE  myocardial delayed
enhancement
MRI  magnetic resonance
imaging/image
SSFP  steady-state free
precession
TTE  transthoracic
echocardiogramn frac
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Myocardial Strain in Duchenne Muscular Dystrophy April 7, 2009:1204–10tratified the patients age 10 years without MDE into
hose with normal EF and those with reduced EF. Thus,
roup C comprised DMD patients age 10 years with
ormal EF and negative MDE. Group D comprised DMD
atients age 10 years with reduced EF (55%) but
egative MDE. Finally, Group E patients comprised DMD
atients age10 years with reduced EF and positive MDE.
RI acquisition. The MRI studies were conducted either
n a Siemens 3-T Trio (Siemens Medical Solutions,
alvern, Pennsylvania/Erlangen, Germany) or on a 1.5-T
E Signa Excite (GE Healthcare, Milwaukee, Wisconsin).
he type of machine used on the DMD patients and control
ubjects was based solely on clinical availability, independent
f the patient’s clinical status.
maging protocols. VENTRICULAR VOLUMETRY AND GLOBAL
UNCTIONAL IMAGING. Cardiac functional imaging was
erformed with retrospective electrocardiogram (ECG)-
ating, segmented steady-state free precession (SSFP)
echnique after localized shimming and/or frequency
djusting. Subjects were breath-held as tolerated; for
hose subjects who could not adequately breath-hold, a
ree breathing technique with multiple signal averaging
as used. Standard imaging included a short-axis stack of
ine SSFP images from cardiac base to apex; the short
xis was prescribed as the perpendicular plane to the left
entricular long axis in 2- and 4-chamber views as
reviously described (20,21). Typical scan parameters
ncluded field of view 32 to 38 cm, slice thickness 5 to 6
m, gap 1 to 2 mm, number of excitations 2 (breath
old; 4 to 5 for free breathing), echo time/repetition time
TE/TR) 1.4/2.8 (Siemens Medical Solutions), TE/TR
.0/4.0 (GE Healthcare), and in-plane resolution 1.2 to
.2 mm. A minimum of 12 slices were performed, with
0 phases/slice. The typical temporal resolution of the
ine SSFP images was 30 to 40 ms and was adjusted
ccording to the patient’s heart rate and ability to breath-hold.
he radiofrequency flip angles were set between 50° and 70°,
ependent on the patient’s weight and height and the specific
bsorption rate level.
Figure 2 Cardiac Magnetic Resonance Image
From the early systolic 4-chamber view (left), the short-axis of the midventricle is
with a tag sequence (middle). Mesh overlaying of the tag image with a harmonic pYOCARDIAL STRAIN IMAGING. Tagged cine MRIs were
cquired in the short axis of the midventricle at the level of
he papillary muscles (Fig. 2) with an ECG-triggered
egmented k-space fast gradient echo sequence with spatial
odulation of magnetization in orthogonal planes. Tag
maging was performed before administration of gadolin-
um. Grid tag spacing was 7 to 8 mm. The scan parameters
sed were: field of view (30 – 32)  (25 – 26) cm2, slice
hickness 6 mm, flip angle 20°, TE/TR 3 ms/6.6 ms (GE
ealthcare), TE/TR 3 ms/4.2 ms (Siemens Medical Solu-
ions), views/segment 8 (GE Healthcare), views/segment 7
o 9 (Siemens Medical Solutions).
DE. MDE imaging was performed on DMD patients
hen intravenous access was obtained (n  54); no MDE
maging was performed in the control group. MDE imaging
as performed via a FLASH inversion sequence recovery
rotocol 10 min after 0.2 mmol/kg gadolinium diethylene-
riamine penta-acetic acid (Gd-DTPA) injection (16,22,23).
DE imaging was considered positive if any area of the
id-myocardium showed hyperenhancement (Fig. 3) as as-
essed by 3 independent expert observers (R.J.F., W.M.G., and
.N.H.) (24).
ata analysis: ventricular volumetry, global functional
ata, and MDE status. Ventricular volumes, mass, and
lobal function were assessed via standard planimetry tech-
iques with semi-automated computer software (QMASS
ersion 6.1.5, Medis Medical Imaging Systems, Leiden, the
etherlands) by expert readers (R.J.F., W.M.G., and
.N.H.) (25,26). This assessment was performed on
ICOM images from either scanner, independent of ven-
or or field strength (27,28). MDE status, ventricular
olumes, mass, and EF were tabulated for each subject and
hen exported to a spreadsheet file.
yocardial strain analysis. Tagged images were analyzed
ith the HARmonic Phase (HARP, Diagnosoft, Palo
lto, California) technique (19,29 –33). Only the mid-
entricular slice was analyzed, on the basis of our expe-
ience and others (19) of limited reproducibility of the
asal and apical slices. Details of cc analysis are de-
ed at the level of the papillary muscles
(HARP) software (Diagnosoft, Inc.) is shown (right).obtain
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April 7, 2009:1204–10 Myocardial Strain in Duchenne Muscular Dystrophycribed in the Online Appendix. The cc data were
xported to a spreadsheet file for analysis. An average of
ll the regional values/subject was calculated as a com-
osite regional strain value, to allow for comparison
urposes (19,30 –32,34). The average cc values for all
ubjects were then tabulated and grouped according to
he group stratification criteria (see the Methods section)
Fig. 1). All HARP strain analyses were performed by an
xpert reader (K.N.H.). To assess interobserver variabil-
ty of HARP strain analyses, a second expert reader
W.M.G.) performed the same analysis on subsets of
atient (n  10) and control (n  5) data.
tatistical analyses. All statistical analyses were performed
ith SPSS software version 16 (SPSS Inc., Chicago, Illi-
ois). Differences in the means between the groups for all
arametric data were assessed by analysis of variance. Due to
nequal variance, post-hoc analysis was performed with the
ames-Howell procedure to determine significance. For
onparametric data, the Mann-Whitney U test was per-
ormed. Probability values of 0.05 were considered statis-
ically significant.
Figure 3 MDE, an MRI Marker of Myocardial Fibrosis
Myocardial delayed enhancement (MDE) in the short-axis (A) and long-axis (B) pla
myocardial fibrosis in a 20-year-old Duchenne muscular dystrophy patient, as show
omparison of MRI Findings Between Control and DMD Groups
Table 1 Comparison of MRI Findings Between Control and DMD
Parameters Group A (n  16) Group B (n  16)
Age (yrs) 14.5 8.4* 8.4 0.84*
Heart rate (beats/min) 81 15* 106 15
LVM/BSA 2.0 1.2 2.0 0.76*
LVEDV/BSA 2.0 0.96 1.6 0.70
ED mass/HT2.7 18.5 6.3* 25.8 5.0
EF (%) 65.1 3.7 65.5 3.7
cc (%) 18.6 2.0* 14.4 1.1*
MDE performed 0/16 7/16
MDE result — Negative
roup A  control; Group B  Duchenne muscular dystrophy (DMD), age 10 years; Group C  DM
roup D  DMD, age 10 years, reduced EF, and MDE negative; Group E  DMD, age 10 years
2.7 2.7ECG  electrocardiogram; ED mass/HT  left ventricular end-diastolic mass/height ; LVEDV/BSA
entricular mass z-score adjusted to body surface area; MRI  magnetic resonance imaging; cc  circuesults
tudy population. Data from 70 DMD patients (age 7 to
6 years) and 16 control subjects (age 6 to 34 years) were
ncluded in the study. The MDE sequence imaging was
erformed in 54 of 70 DMD patients; MDE imaging was
ot performed in 16 of 70 patients (9 from Group B, 5 from
roup C, and 2 from Group D) lacking intravenous access.
atient stratification (Fig. 1) revealed the following: Group
(control subjects, n  16); Group B (DMD patients age
10 years, n  16), Group C (DMD patients age 10
ears with normal EF, n  31), Group D (DMD patients
ge 10 years with low EF but no MDE, n  12), and
roup E (DMD patients age 10 years with low EF and
ositive MDE, n  11). Demographic data of the DMD
nd control groups were not significantly different (Table 1).
he ECG findings of relative tachycardia were found in
MD patients, consistent with prior publications (35).
one of the patients had ventricular hypertrophy, as evi-
enced by a normal mass–volume ratio and normal wall
hicknesses (Online Table 1).
dicates
he white arrows.
ups
Group C (n  31) Group D (n  12) Group E (n  11)
13.0 2.9* 15.8 4.5 17.3 5.3
101 16 103 6 112 19
1.5 0.60 0.88 1.7* 0.46 1.1
2.1 1.4 0.20 3.9 2.6 3.8
26.7 4.2 28.8 9.2* 37 10
64.1 5.5* 47.4 7.4* 32.7 14.9
12.4 2.1* 10 1.9* 6.5 1.2
26/31 10/12 11/11
Negative Negative Positive
10 years, normal ejection fraction (EF), and myocardial delayed enhancement (MDE) negative;
ed EF, and MDE positive. *p value (0.05) is significant compared with the preceding group.nes in
n by tGro
D, age
, reduc left ventricular end-diastolic volume z-score adjusted to body surface area; LVM/BSA  left
mferential strain.
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Myocardial Strain in Duchenne Muscular Dystrophy April 7, 2009:1204–10ircumferential strain values. CONTROL SUBJECT STRAIN
ATA. All Group A subjects had cc 16% and normal EF
Figs. 4 and 5B). Given the wide range of age and mean heart
ate of control subjects, we performed an analysis of the
ffect of heart rate on cc. We divided control subjects into
ge 10 years (n  7, mean age  8  1.3 years) or age
10 years (n  9, mean age  19.6  8 years). There was
o significant difference in cc (19.3% vs. 18.2%, p 
S) or EF (66.3% vs. 64.2%, p  NS) between the
ubgroups, despite significant differences in heart rate be-
ween the groups (90 beats/min vs. 75 beats/min, p 0.03).
Figure 4 Box Plot of EF/Strata
Normal EF is seen in control subjects (Group A) and also in DMD patients
(Groups B and C). Progressive decline in EF is seen in older patients (Group
D), with further decline once MDE is present (Group E). Abbreviations as in
Figure 1.
Figure 5 Graphs of cc Values/Strata
(A) Bar graph shows statistically significant (p  0.05) progressive reduction in circum
(Group A). In addition, each stratum is statistically different from other strata (B vs
(Groups B to E). No control subjects have  16%, and no DMD subjects havecc ccMD PATIENT STRAIN DATA. No DMD patient had
cc16%, even in the youngest DMD patients (Group B) with
ormal EF. Compared with the control subjects, 2 DMD
roups (Group B and C) had similar EF (65.5% vs. 64.1%,
 NS) (Figs. 4 and 5B, Table 1). However, despite the
imilarity of EF, cc was significantly decreased in both
roup B (14.4% vs. 18.6%, p  0.001) and Group C
12.4% vs. 14.4%, p  0.001) compared with the
ontrol group. Furthermore, the presence of reduced EF
47.4%, Group D) was associated with a further reduction in
cc (10% vs. 12.4%, p  0.001) compared with the
ge-matched DMD cohort with normal EF (64.1%, Group
). The presence of overt ventricular dysfunction (EF 
2.7%) and MDE (Group E) was associated with signifi-
antly decreased cc compared with Group D (6.5% vs.
10%, p  0.0001) (Figs. 4 and 5A).
ariability of HARP strain measurements. Two inde-
endent observers (W.M.G., K.N.H.) blindly performed
eparate quantitative strain analyses of myocardial cine
R-tagging images in 10 DMD patients and 5 control
ubjects. As previously shown (36), interobserver variability
as low, with a mean difference of 0.009%.
iscussion
major finding of this study is the detection of abnormal
cc in young (age 10 years, Group B) DMD patients
espite normal EF. There was further reduction in cc in
lder DMD patients with normal EF (Group C), a finding
imilar to that previously reported by Ashford et al. (19) in
cohort of DMD patients similar in mean age to Group C.
t is important to note that the mean age of Groups B and
ial strain (cc) for each stratum (Groups B to E) compared with control subjects
vs. D, D vs. E). (B) Scatter graph of cc of control (Group A) and DMD patients
16%. *Mean  of each group. Abbreviations as in Figure 1.ferent
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April 7, 2009:1204–10 Myocardial Strain in Duchenne Muscular Dystrophydiffers by almost 5 years, again placing emphasis on the
oung age at which reduced strain can be observed. In
ddition, with advancing age and reduced EF, there was
urther reduction in cc. A relationship between strain
eduction and disease severity was further exemplified when
DE, the MRI marker of myocardial fibrosis, was consid-
red. Taken together, we concluded that cc might be of
alue in defining the natural history of cardiac dysfunction
n DMD and be a useful marker to assess therapeutic efficacy
n young patients with normal global cardiac function.
It is not surprising to find abnormal cc in relatively young
MD boys. Duchenne muscular dystrophy results from a
utation in dystrophin, a large cytoskeletal protein localized
o the inner surface of the sarcolemma membrane (1).
ystrophin mutation results in greatly reduced or absent
ystrophin leading to a weakened sarcolemma that is more
asily damaged during muscle contraction. A long-standing
ypothesis regarding DMD disease pathogenesis is that loss
f membrane integrity is a primary event leading to degen-
ration of myocytes. Intermittent tears in the cell membrane
ermit influx of calcium that then functions as a primary
nducer of a destructive cascade culminating in myocyte
ecrosis and replacement fibrosis (37–39). Recent observa-
ions that the angiotensin II receptor blocker losartan
educes fibrotic disease in the mdx mouse implicate involve-
ent of the transforming growth factor beta-1 and angio-
ensin II effector pathways in DMD pathogenesis (40).
ollectively, these processes lead to necrosis, inflammation,
nd fibrosis manifested clinically by a progressive cardiac
ysfunction (37,38,40,41). Because these processes are on-
oing even in early stages of disease, abnormal cc should be
xpected.
There has long been interest in identification of early
ndicators of abnormal cardiac function in the DMD
opulation. However, TTE evidence of cardiac dysfunc-
ion is not evident until late in the disease course
2,3,13,14,41,42). Studies using tissue Doppler imaging
nd strain rate imaging might detect early alteration in
ystolic and/or diastolic function compared with conven-
ional imaging indexes such as EF and ventricular dimen-
ions in DMD boys. In addition, TTE-based ultrasonic
issue characterization has been advocated as a means to
haracterize preclinical myocardial changes in DMD pa-
ients via integrated backscatter indexes (10,43). Although
ltrasonic tissue characterization might prove to be useful
or myocardial assessment, it too is limited by acoustic
indows and angle dependence (10,43–45).
tudy limitations. Although significant differences in cc
ere demonstrated between young DMD patients with
ormal EF and older patients with reduced EF, this is a
ross-sectional and not a serial study. Accordingly, repeat
erial examinations would provide a more robust analysis of
ongitudinal cc in this patient population. In the current
tudy, only the midventricular slice was analyzed secondary
o our experience of limited reproducibility of the basal and
pical slices. Studies were performed with 2 different ven-ors and magnetic field strengths, but we do not believe this
onfounds our data (27). Further MDE imaging was not
erformed in some younger patients with normal EF or in
ny of the control subjects. In our experience, MDE occurs
ate in the course of the disease, so it can reasonably be
xpected to have been absent in those individuals. Lastly,
ue to the size of our study population, we were not able to
tratify cc on the basis of dystrophin genotype; such
tratification might require multicenter studies. Despite
hese limitations, we propose that using cc determined by
ARP analysis seems to be a sensitive indicator of cardiac
ysfunction in DMD patients.
onclusions
he MRI strain analysis in DMD patients demonstrates
ccult cardiovascular dysfunction in the presence of normal
lobal function. The occult dysfunction progresses to global
ysfunction with advancing age. Detection of such strain
bnormalities might allow a better definition of the natural
istory of DMD cardiac dysfunction and also might provide
useful surrogate index to assess therapeutic efficacy.
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